Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Infect Control Hosp Epidemiol ; 33(8): 817-30, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22759550

ABSTRACT

BACKGROUND: Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly emerging worldwide. Control group selection is critically important when analyzing predictors of antimicrobial resistance. Focusing on modifiable risk factors can optimize prevention and resource expenditures. To identify specific predictors of CRE, patients with CRE were compared with 3 control groups: (1) patients with extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae, (2) patients with non-ESBL-containing Enterobacteriaceae, and (3) uninfected controls. DESIGN: Matched multivariable analyses. PATIENTS AND SETTING: Patients possessing CRE that were isolated at Detroit Medical Center from September 1, 2008, to August 31, 2009. METHODS: Patients were matched (1∶1 ratio) to the 3 sets of controls. Matching parameters included (1) bacteria type, (2) hospital/facility, (3) unit/clinic, (4) calendar year, and (5) time at risk (ie, from admission to culture). Matched multivariable analyses were conducted between uninfected controls and patients with CRE, ESBL, and non-ESBL Enterobacteriaceae. Models were also designed comparing patients with CRE to patients with ESBL, patients with non-ESBL Enterobacteriaceae, and all 3 non-CRE groups combined. RESULTS: Ninety-one unique patients with CRE were identified, and 6 matched models were constructed. Recent (less than 3 months) exposure to antibiotics was the only parameter that was consistently associated with CRE, regardless of the group to which CRE was compared, and was not independently associated with isolation of ESBL or non-ESBL Enterobacteriaceae. CONCLUSIONS: Exposure to antibiotics within 3 months was an independent predictor that characterized patients with CRE isolation. As a result, antimicrobial stewardship efforts need to become a major focus of preventive interventions. Regulatory focus regarding appropriate antimicrobial use might decrease the detrimental effects of antibiotic misuse and spread of CRE.


Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae , beta-Lactam Resistance/drug effects , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/adverse effects , Case-Control Studies , Drug Utilization , Enterobacteriaceae/metabolism , Female , Humans , Male , Middle Aged , Multivariate Analysis , Proportional Hazards Models , Risk Factors , beta-Lactamases/biosynthesis
2.
Antimicrob Agents Chemother ; 56(5): 2452-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22354290

ABSTRACT

In published studies, cohorts of patients with bacteremia due to vancomycin-resistant Enterococcus (VRE) have predominantly been infected with Enterococcus faecium. Little is known about the epidemiology and outcomes associated with bacteremia due to VR Enterococcus faecalis. A retrospective study of isolates obtained from January 2008 to October 2010 was conducted at Detroit Medical Center (DMC). Unique patients with blood cultures positive for VRE were reviewed. Outcomes were analyzed using logistic regression. During the study period, 105 cases of bacteremia due to VR E. faecalis and 197 cases of bacteremia due to VR E. faecium were identified. The mean age in the study cohort was 61.5 ± 15 years; 162 subjects (53.6%) were male. After controlling for a propensity score, bacteremia due to VR E. faecalis was associated with >2-fold-lower in-hospital mortality than bacteremia due to VR E. faecium. Interestingly, bacteremia due to VR E. faecalis was associated with longer hospital stay after VRE isolation, although total length of stay was similar for groups with VR E. faecalis and VR E. faecium. Bacteremia due to VR E. faecalis was associated with a >2-fold-lower risk for mortality than bacteremia due to VR E. faecium, possibly due to the availability of ß-lactam therapeutics for treatment of VR E. faecalis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteremia/drug therapy , Enterococcus faecalis/pathogenicity , Enterococcus faecium/pathogenicity , Gram-Positive Bacterial Infections/drug therapy , Vancomycin/administration & dosage , beta-Lactams/administration & dosage , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Bacteremia/microbiology , Bacteremia/mortality , Enterococcus faecalis/isolation & purification , Enterococcus faecium/isolation & purification , Female , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Hospital Mortality , Humans , Logistic Models , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , United States/epidemiology , Vancomycin/therapeutic use , Vancomycin Resistance , beta-Lactams/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...